Page 3.14

The FDA may soon join forces with personal genomics companies like 23andMe and CIMR in order to draw associations between genotypes and adverse drug reactions. ScienceBlogger Revere from Genetic Future posted that before such a collaborationis considered, genomics companies must recruit more—and more diverse—participants and improve methodology to gather “extremely accurate and detailed” clinical data about them and their drug regimens. “Any genome-wide association study is only as good as the clinical data it’s based around,” he wrote.